This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 Jun 21;371(9630):2059-60.

doi: 10.1016/S0140-6736(08)60894-6.

Laquinimod, a new oral drug for multiple sclerosis

B Mark Keegan¹, Brian G Weinshenker

Affiliations

PMID: 18572062
DOI: 10.1016/S0140-6736(08)60894-6

Comment

Laquinimod, a new oral drug for multiple sclerosis

B Mark Keegan et al. Lancet. 2008.

. 2008 Jun 21;371(9630):2059-60.

doi: 10.1016/S0140-6736(08)60894-6.

Authors

B Mark Keegan¹, Brian G Weinshenker

Affiliation

¹ Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. keegan.bmark@mayo.edu

PMID: 18572062
DOI: 10.1016/S0140-6736(08)60894-6

No abstract available

PubMed Disclaimer

Comment on

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5062 Study Group. Comi G, et al. Lancet. 2008 Jun 21;371(9630):2085-92. doi: 10.1016/S0140-6736(08)60918-6. Lancet. 2008. PMID: 18572078 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database